李海玲,车文良

• 1:上海同济大学附属第十人民医院心脏中心

摘要(Abstract)：

<正>介入心脏病学从经皮冠状动脉腔内成形术(percutaneous transluminal coronary angioplasty,PTCA)、裸金属支架(bare metal stent,BMS)置入术到药物洗脱支架(drugeluting stent,DES)置入术,经历了数次跨越式发展,目前进入了生物可吸收支架(bioresorbable vascular scaffold,BVS)置

关键词(KeyWords)： 生物可吸收支架;急性ST段抬高心肌梗死

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 李海玲,车文良

参考文献(References)：

• [1]Mukete BN,van der Heijden LC,Tandjung K,et al.Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up:A systematic review and meta-analysis of studies.Int J Cardiol,2016,221:1087-1094.
• [2]Cassese S,Byrne RA,Ndrepepa G,et al.Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents:a meta-analysis of randomised controlled trials.Lancet,2016,387(10018):537-544.
• [3]Serruys PW,Chevalier B,Dudek D,et al.A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions(ABSORBⅡ):an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.Lancet,2015,385(9962):43-54.
• [4]朱永翔,张瑶俊,窦克非,等.生物可吸收支架治疗冠状动脉分叉病变的研究进展.中国介入心脏病学杂志,2016,24(9):526-529.
• [5]Kajiya T,Liang M,Sharma RK,et al.Everolimus-eluting bioresorbable vascular scaffold(BVS)implantation in patients with ST-segment elevation myocardial infarction(STEMI).Euro Intervention,2013,9(4):501-504.
• [6]Wiebe J,M9llmann H,Most A,et al.Short-term outcome of patients with ST-segment elevation myocardial infarction(STEMI)treated with an everolimus-eluting bioresorbable vascular scaffold.Clin Res Cardiol,2014,103(2):141-148.
• [7]Diletti R,Karanasos A,Muramatsu T,et al.Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction:BVS STEMI first study.Eur Heart J,2014,35(12):777-786.
• [8]Kocka V,MalM,Tou2ek P,et al.Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction:a prospective multicentre study‘Prague 19’.Eur Heart J,2014,35(12):787-794.
• [9]Kochman J,Tomaniak M,Pietrasik A,et al.Bioresorbable everolimus-eluting vascular scaffold in patients with ST-segment elevation myocardial infarction:Optical coherence tomography evaluation and clinical outcomes.Cardiol J,2015,22(3):315-322.
• [10]Ielasi A,Cortese B,Varricchio A,et al.Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction:insights from the multicentre"Registro ABSORB Italiano"(RAI registry).Euro Intervention,2015,11(2):157-162.
• [11]Cortese B,Ielasi A,Romagnoli E,et al.Clinical comparison with short-term follow-up of bioresorbable vascular scaffold versus everolimus-eluting stent in primary percutaneous coronary interventions.Am J Cardiol,2015,116(5):705-710.
• [12]Brugaletta S,Gori T,Low AF,et al.Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in STsegment elevation myocardial infarction:1-year results of a propensity score matching comparison:the BVS-EXAMINATION Study(bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).JACC Cardiovasc Interv,2015,8(1 Pt B):189-197.
• [13]Rber L,Onuma Y,Brugaletta S,et al.Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold(Absorb BVS)versus the durable polymer everolimus-eluting metallic stent(XIENCE)in patients with acute ST-elevation myocardial infarction:rationale and design of the randomised TROFIⅡstudy.Euro Intervention,2016,12(4):482-489.
• [14]SabatéM,Windecker S,I1iguez A,et al.Everolimus-eluting bioresorbable stent vs.durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction:results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFIⅡtrial.Eur Heart J,2016,37(3):229-240.
• [15]Brown AJ,Mc Cormick LM,Braganza DM,et al.Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation.Catheter Cardiovasc Interv,2014,84(1):37-45.
• [16]G9rge G,Haude M,Ge J,et al.Intravascular ultrasound after low and high inflation pressure coronary artery stent implantation.J Am Coll Cardiol,1995,26(3):725-730.
• [17]Hur SH,Kitamura K,Morino Y,et al.Efficacy of postdeployment balloon dilatation for current generation stents as assessed by intravascular ultrasound.Am J Cardiol,2001,88(10):1114-1119.
• [18]Costopoulos C,Latib A,Naganuma T,et al.Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.Catheter Cardiovasc Interv,2015,85(1):E10-E15.
• [19]Mattesini A,Secco GG,Dall'Ara G,et al.ABSORB biodegradable stents versus second-generation metal stents:a comparison study of 100 complex lesions treated under OCT guidance.JACC Cardiovasc Interv,2014,7(7):741-750.